What is the history of Pyruvate Kinase Deficiency?

Pyruvate Kinase Deficiency (PKD) was first identified in 1961 by Dr. William Valentine and his colleagues, who discovered it as a cause of non-spherocytic hemolytic anemia. Since its discovery, our understanding of Pyruvate Kinase Deficiency has shifted from a poorly understood blood disorder to a well-characterized metabolic condition linked to specific mutations in the PKLR gene.

Who first discovered Pyruvate Kinase Deficiency?

In 1961, Dr. William N. Valentine, along with K.R. Tanaka and S. Miwa, published a landmark paper in Blood describing a new form of hereditary nonspherocytic hemolytic anemia. They identified that patients with this condition lacked the enzyme pyruvate kinase in their red blood cells, which prevents the cells from producing enough energy (ATP) to maintain their structure, leading to premature destruction (hemolysis).

How has our understanding of Pyruvate Kinase Deficiency evolved?

Initially, Pyruvate Kinase Deficiency was often confused with other hemolytic anemias, such as glucose-6-phosphate dehydrogenase (G6PD) deficiency. Over the last six decades, the evolution of genomic sequencing has allowed researchers to identify over 300 distinct mutations in the PKLR gene. This shift from clinical observation to molecular diagnosis has been crucial for providing accurate prognosis and family counseling.

What were the major milestones in treating Pyruvate Kinase Deficiency?

For decades, management was limited to supportive care, such as blood transfusions and splenectomy. The landscape changed dramatically with the following milestones:

• 1961: The biochemical basis of Pyruvate Kinase Deficiency is identified.


• 1990s: The PKLR gene is mapped and cloned, enabling genetic testing.


• 2022: The FDA approved mitapivat, the first disease-modifying therapy specifically designed to activate the pyruvate kinase enzyme.

How has patient advocacy changed the landscape?

Historically, patients with Pyruvate Kinase Deficiency were isolated due to the rarity of the condition. Today, global patient organizations and platforms like DiseaseMaps.org—which currently supports a community of 6 members living with Pyruvate Kinase Deficiency—have empowered families to share experiences, participate in clinical registries, and accelerate the pace of research.

Next steps

• Consult a hematologist specializing in rare red cell enzymopathies.


• Connect with the Pyruvate Kinase Deficiency community at DiseaseMaps.org to share your journey.


• Speak with a genetic counselor to discuss PKLR gene testing for family planning.

Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Pyruvate kinase deficiency.


• Orphanet: Pyruvate kinase deficiency (ORPHA:765).


• OMIM (Online Mendelian Inheritance in Man): Pyruvate kinase deficiency of red cells; PKRD.


• PubMed: Valentine WN, et al. "Hereditary hemolytic anemia with hexokinase deficiency." (Historical context on enzyme defects).